This cross-sectional observational study evaluated the availability and
switching patterns of branded generics of Vildagliptin, an antidiabetic
medication, in a real-world setting. Data from 967 prescriptions
obtained from various pharmacies over a 3-month period post-patent
expiration were analyzed. The study revealed a diverse range of branded
generics, highlighting challenges in consistent availability. Switching
patterns were observed, with a significant proportion of patients
deviating from the initially prescribed branded generic. These findings
emphasize the need for strategies to improve availability and promote
appropriate use of branded generics, enhancing cost-effective diabetes
management and patient care. Further research is warranted to
investigate factors influencing brand switching behaviors and their
impact on patient outcomes. This study provides valuable insights for
optimizing the prescribing and availability of branded generics,
ultimately enhancing the quality of care for patients requiring
Vildagliptin treatment.